2.50

0.81% 0.02

After Hours: 2.49 -0.010 -0.40%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $2.50, with a volume of 1.10M. It is up +0.81% in the last 24 hours and up +5.49% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Previous Close:

$2.48

Open:

$2.48

24h Volume:

1.10M

Relative Volume:

0.58

Market Cap:

$177.93M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-0.9363

EPS:

-2.67

Net Cash Flow:

$-108.55M

1W Performance:

+0.81%

1M Performance:

+5.49%

6M Performance:

+62.34%

1Y Performance:

-39.76%

1-Day Range:

$2.44

$2.54

1-Week Range:

$2.37

$2.55

52-Week Range:

$1.085

$5.10

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1130)

Industry

Biotechnology (634)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

110

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	2.50	240.35M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	421.03	110.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	702.75	76.23B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	460.76	61.08B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	914.59	56.55B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	203.56	43.00B	447.02M	-1.18B	-906.14M	-6.1812

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

Nov 19, 2025

Using economic indicators to assess C4 Therapeutics Inc. potentialWall Street Watch & Accurate Entry/Exit Alerts - newser.com

Nov 19, 2025

C4 Therapeutics Inc. stock trend forecastJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com

Nov 19, 2025

How C4 Therapeutics Inc. stock responds to policy changesJuly 2025 Sentiment & Long-Term Safe Investment Plans - newser.com

Nov 19, 2025

Nov 18, 2025

Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 18, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire

Nov 18, 2025

Nov 17, 2025

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 17, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 17, 2025

Nov 16, 2025

Using data models to predict C4 Therapeutics Inc. stock movement2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com

Nov 16, 2025

What data driven models say about C4 Therapeutics Inc.’s futureMarket Performance Summary & Fast Moving Stock Watchlists - newser.com

Nov 16, 2025

Nov 15, 2025

Volatility clustering patterns for C4 Therapeutics Inc.Trade Entry Summary & Safe Capital Allocation Plans - newser.com

Nov 15, 2025

Live market analysis of C4 Therapeutics Inc.July 2025 Recap & Capital Efficient Trade Techniques - newser.com

Nov 15, 2025

Is C4 Therapeutics Inc. stock positioned for digital transformationJuly 2025 WrapUp & Low Volatility Stock Suggestions - newser.com

Nov 15, 2025

Nov 14, 2025

Camp4 Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 14, 2025

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 14, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 14, 2025

How C4 Therapeutics Inc. stock benefits from strong dollarJuly 2025 Retail & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará

Nov 14, 2025

Nov 12, 2025

Will earnings trigger a reversal in C4 Therapeutics Inc.July 2025 Drop Watch & Weekly Watchlist for Consistent Profits - newser.com

Nov 12, 2025

Can trapped investors hope for a rebound in C4 Therapeutics Inc.2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com

Nov 12, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 12, 2025

Nov 11, 2025

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Nov 11, 2025

Nov 10, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

Nov 10, 2025

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 10, 2025

Nov 07, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com

Nov 07, 2025

Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 07, 2025

Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 07, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 07, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 07, 2025

C4 Therapeutics Raises Cash And Wins Wall Street’s Favor - Finimize

Nov 07, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 07, 2025

Nov 06, 2025